1-4 of 4
Renee Lichtenstein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Clinical Trials & Observations
Jennifer E. Amengual, Renee Lichtenstein, Jennifer Lue, Ahmed Sawas, Changchun Deng, Emily Lichtenstein, Karen Khan, Laine Atkins, Aishling Rada, Hye A. Kim, Codruta Chiuzan, Matko Kalac, Enrica Marchi, Lorenzo Falchi, Mark A. Francescone, Lawrence Schwartz, Serge Cremers, Owen A. O’Connor
Journal: Blood
Blood (2018) 131 (4): 397–407.
https://doi.org/10.1182/blood-2017-09-806737
Published: 2018
Includes: Supplemental data
Journal Articles

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Jennifer E Amengual, MD, Renee Lichtenstein, Celeste Rojas, Ahmed Sawas, MD, Changchun Deng, MD PhD, Emily Lichtenstien, Karen Kahn, Jennifer Kimberly Lue, MD, Yuxuan Liu, PhD, Changhong Qiao, Renu Nandakumar, PhD, Serge Cremers, PhD, Owen A. O'Connor, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1824.
https://doi.org/10.1182/blood.V128.22.1824.1824
Published: 2016
Journal Articles

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

Owen A. O'Connor, MD PhD, Kelly Zullo, MS, Enrica Marchi, MD PhD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Donald Steven Colbourn, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Michael Smith, RN, Luigi Scotto, PhD, Jennifer E Amengual, MD
Journal: Blood
Blood (2015) 126 (23): 1282.
https://doi.org/10.1182/blood.V126.23.1282.1282
Published: 2015
Journal Articles

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

Ahmed Sawas, MD, Joseph M. Connors, MD, John G. Kuruvilla, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Diego Villa, MDMPH, Michael Crump, MD, Owen A. O'Connor, MD PhD
Journal: Blood
Blood (2015) 126 (23): 586.
https://doi.org/10.1182/blood.V126.23.586.586
Published: 2015